{"id":806,"date":"2025-11-13T14:30:59","date_gmt":"2025-11-13T14:30:59","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/11\/13\/ms-drug-fenebrutinib-shows-unprecedented-results-in-trials\/"},"modified":"2025-11-13T14:30:59","modified_gmt":"2025-11-13T14:30:59","slug":"ms-drug-fenebrutinib-shows-unprecedented-results-in-trials","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/11\/13\/ms-drug-fenebrutinib-shows-unprecedented-results-in-trials\/","title":{"rendered":"MS drug fenebrutinib shows \u2018unprecedented results\u2019 in trials"},"content":{"rendered":"<p>Genentech&#8216;s experimental oral therapy fenebrutinib has become the first Bruton\u2019s tyrosine kinase (BTK) inhibitor to show positive Phase 3 results in both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS), the company announced. In what Genentech called &#8220;unprecedented results,&#8221; two late-stage trials testing the therapy in these indications have met their primary [&#8230;]<\/p>\n<p>The post <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2025\/11\/13\/ms-drug-fenebrutinib-shows-unprecedented-results-trials\/\">MS drug fenebrutinib shows &#8216;unprecedented results&#8217; in trials<\/a> appeared first on <a href=\"https:\/\/multiplesclerosisnewstoday.com\">Multiple Sclerosis News Today<\/a>.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2025\/11\/13\/ms-drug-fenebrutinib-shows-unprecedented-results-trials\/\" rel=\"nofollow noopener\" target=\"_blank\">multiplesclerosisnewstoday.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Genentech&#8216;s experimental oral therapy fenebrutinib has become the first Bruton\u2019s tyrosine kinase (BTK) inhibitor to show positive Phase 3 results in both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS), the company announced. In what Genentech called &#8220;unprecedented results,&#8221; two late-stage trials testing the therapy in these indications have met their primary&#8230;<\/p>\n","protected":false},"author":0,"featured_media":807,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-806","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=806"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/806\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/807"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}